Published in

Bentham Science Publishers, Mini-Reviews in Organic Chemistry, 7(19), p. 798-810, 2022

DOI: 10.2174/1570193x19666220119120211

Links

Tools

Export citation

Search in Google Scholar

The Neuropharmacological Potential of Piperazine Derivatives: A Mini- Review

Journal article published in 2022 by Saad Alghamdi ORCID, Mohammed M. Alshehri ORCID, Mohammad Asif ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Piperazine is a six-membered heterocyclic ring with two nitrogen atoms at positions one and four. This piperazine moiety can be present in a slew of well-known medicines that have pharmacophoric effects on a variety of receptors. Various piperazine analogs have core biological activities involving the activation of monoamine pathways, primarily on neurotransmitter receptors. As a result, piperazine analogs have a wide range of central clinical uses, including anxiolytic, antipsychotic, and antidepressant. Due to its stimulant and euphoric effects, benzyl-piperazine is the prototype of piperazine analogs, and this molecule is the main substance of recreational drugs. This review focuses on the activity of piperazine pharmacophore on diverse neurotransmitter receptors used therapeutically as anxiolytics (buspirone), antidepressants (vortioxetine), antipsychotics (clozapine), and other drugs.